Carl Byrnes
Stock Analyst at Northland Securities
(0.24)
# 4,264
Out of 4,453 analysts
318
Total ratings
36.7%
Success rate
-4.4%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTB Connect Biopharma Holdings | Maintained: Buy | $7.5 | $2.07 | +262.32% | 3 | Apr 24, 2026 | |
| MDXG MiMedx Group | Maintained: Buy | $10 → $6 | $3.81 | +57.48% | 27 | Apr 17, 2026 | |
| SPRY ARS Pharmaceuticals | Maintained: Buy | $25 | $8.02 | +211.72% | 2 | Apr 15, 2026 | |
| RCEL AVITA Medical | Maintained: Buy | $10 | $3.92 | +155.10% | 2 | Mar 26, 2026 | |
| BLFS BioLife Solutions | Reiterated: Buy | $34 | $27.50 | +23.64% | 37 | Mar 24, 2026 | |
| TLSI TriSalus Life Sciences | Rated: Buy | $13 → $8 | $4.37 | +83.07% | 5 | Mar 23, 2026 | |
| MDAI Spectral AI | Maintained: Buy | $6 | $1.67 | +259.28% | 12 | Mar 19, 2026 | |
| SNWV SANUWAVE Health | Maintained: Buy | $55 | $7.63 | +620.84% | 4 | Mar 16, 2026 | |
| INDV Indivior Pharmaceuticals | Maintained: Buy | $50 | $41.29 | +21.09% | 12 | Feb 27, 2026 | |
| BWAY BrainsWay | Maintained: Buy | $12 → $15 | $14.54 | +3.16% | 14 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.48 | +187.36% | 18 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 → $4 | $0.41 | +875.61% | 39 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.6729 | +643.05% | 4 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $3 | $3.15 | n/a | 34 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $2 → $1.25 | $16.35 | n/a | 12 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $2.02 | n/a | 1 | May 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $8 → $1 | $0.0001 | n/a | 24 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $2 | $0.003 | n/a | 24 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 → $2 | $37.14 | n/a | 30 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.17 | n/a | 12 | May 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $45 | $55.39 | n/a | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $13.72 | n/a | 1 | Oct 22, 2018 |
Connect Biopharma Holdings
Apr 24, 2026
Maintained: Buy
Price Target: $7.5
Current: $2.07
Upside: +262.32%
MiMedx Group
Apr 17, 2026
Maintained: Buy
Price Target: $10 → $6
Current: $3.81
Upside: +57.48%
ARS Pharmaceuticals
Apr 15, 2026
Maintained: Buy
Price Target: $25
Current: $8.02
Upside: +211.72%
AVITA Medical
Mar 26, 2026
Maintained: Buy
Price Target: $10
Current: $3.92
Upside: +155.10%
BioLife Solutions
Mar 24, 2026
Reiterated: Buy
Price Target: $34
Current: $27.50
Upside: +23.64%
TriSalus Life Sciences
Mar 23, 2026
Rated: Buy
Price Target: $13 → $8
Current: $4.37
Upside: +83.07%
Spectral AI
Mar 19, 2026
Maintained: Buy
Price Target: $6
Current: $1.67
Upside: +259.28%
SANUWAVE Health
Mar 16, 2026
Maintained: Buy
Price Target: $55
Current: $7.63
Upside: +620.84%
Indivior Pharmaceuticals
Feb 27, 2026
Maintained: Buy
Price Target: $50
Current: $41.29
Upside: +21.09%
BrainsWay
Jan 22, 2026
Maintained: Buy
Price Target: $12 → $15
Current: $14.54
Upside: +3.16%
Nov 14, 2025
Maintained: Buy
Price Target: $10
Current: $3.48
Upside: +187.36%
Nov 5, 2025
Reiterated: Buy
Price Target: $9 → $4
Current: $0.41
Upside: +875.61%
Aug 28, 2025
Maintained: Buy
Price Target: $5
Current: $0.6729
Upside: +643.05%
May 8, 2024
Maintained: Hold
Price Target: $3
Current: $3.15
Upside: n/a
Jul 19, 2023
Rated: Hold
Price Target: $2 → $1.25
Current: $16.35
Upside: n/a
May 22, 2023
Initiated Coverage: Buy
Price Target: $8
Current: $2.02
Upside: n/a
Jan 6, 2023
Downgraded: Sell
Price Target: $8 → $1
Current: $0.0001
Upside: n/a
Nov 23, 2022
Maintained: Buy
Price Target: $10 → $2
Current: $0.003
Upside: n/a
Aug 17, 2022
Maintained: Buy
Price Target: $4 → $2
Current: $37.14
Upside: n/a
May 14, 2020
Rated: Hold
Price Target: n/a
Current: $2.17
Upside: n/a
Oct 22, 2018
Initiated Coverage: Buy
Price Target: $45
Current: $55.39
Upside: n/a
Oct 22, 2018
Initiated Coverage: Buy
Price Target: n/a
Current: $13.72
Upside: n/a